183 related articles for article (PubMed ID: 37804041)
1. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Rienhoff HY; Gill H
Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
[TBL] [Abstract][Full Text] [Related]
2. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
3. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
4. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
5. Top advances of the year: Myeloproliferative neoplasms.
Bhave RR; Mesa R; Grunwald MR
Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
7. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
8. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
Gill H; Leung GMK; Kwong YL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
[TBL] [Abstract][Full Text] [Related]
9. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
10. Unmet Need in Essential Thrombocythemia and Polycythemia Vera.
Kishtagari A; Gerds AT
Hematol Oncol Clin North Am; 2021 Apr; 35(2):295-303. PubMed ID: 33641870
[TBL] [Abstract][Full Text] [Related]
11. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.
Penna D
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833399
[TBL] [Abstract][Full Text] [Related]
12. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
13. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
16. Future therapies for the myeloproliferative neoplasms.
Scherber R; Mesa RA
Curr Hematol Malig Rep; 2011 Mar; 6(1):22-7. PubMed ID: 21080242
[TBL] [Abstract][Full Text] [Related]
17. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
[TBL] [Abstract][Full Text] [Related]
18. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
19. Biology and therapeutic targeting of molecular mechanisms in MPNs.
How J; Garcia JS; Mullally A
Blood; 2023 Apr; 141(16):1922-1933. PubMed ID: 36534936
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
